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Over the last three decades, various approaches have been pursued to increase the
retention of an oral dosage form in the stomach, including floating drug delivery sys-
tems (FDDS), swelling and expanding systems, bioadhesive systems, modified shape sy-
stems, high-density systems and other delayed gastric emptying devices (1). FDDS are
widely explored for gastroretention purposes and have a bulk density lower than gastric
fluids and thus remain buoyant in the stomach without affecting the gastric emptying
rate for a prolonged period of time. While the system is floating on gastric contents, the
drug is released slowly at a desired rate from the system (1, 2).
Sodium alginate (SA) is a widely used natural polymer in various drug delivery sy-
stems. It exhibits favourable biological properties such as non-toxicity, biocompatibility,
biodegradability and ulcer healing traits. Moreover, gelation of dilute solutions of SA oc-
curs on addition of di- and trivalent metal ions by a co-operative process involving con-
secutive G-residues in the a-L-guluronic acid blocks of the alginate chain in a manner
described by the 'egg-box' model (3). The procedure by which gelation is achieved is
similar to the previously reported in situ gelling formulations of sodium alginate (4, 5).
H2-antagonists or proton pump inhibitors are clinically used in treating chronic con-
ditions like peptic ulcer and reflux oesophagitis. H2-antagonists competitively inhibit his-
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tamine actions at all H2-receptors, but are mainly used clinically as inhibitors of gastric
acid secretion (6). Local availability of H2-antagonists in stomach has a greater clinical
significance in treatment of peptic ulcer. Ranitidine (RT), a H2-antagonist, is widely pre-
scribed in active duodenal ulcers, gastric ulcers and gastroesophageal reflux disease. A
conventional dose of 150 mg can inhibit gastric acid secretion up to 5 hours and frequent
administration leads to plasma fluctuations; hence, a sustained release dosage form of
ranitidine is desirable. The short biological half-life of the drug (~2.5–3 hours) also fa-
vors development of a sustained release, gastroretentive formulation (7, 8).
In the present study, an attempt was made to develop a gastroretentive in situ gel-
ling liquid formulation using ranitidine for local release in the stomach. Gastroretentive
in situ gelling liquid formulations were formulated using different grades and concen-
trations of sodium alginate.
EXPERIMENTAL
Materials
Ranitidine (RT) was received as a gift sample from Torrent Pharmaceuticals Ltd (In-
dia). Low viscosity (0.25 Pa s), medium viscosity (6.5 Pa s) and high viscosity (14.0 Pa s)
grades of sodium alginate (SA) were purchased from Sigma-Aldrich (USA). Calcium car-
bonate, sodium citrate and calcium chloride were purchased from S.D. Fine Chem. Ltd
(India). All other chemicals used in the study were of analytical grade.
Methods
Preparation of in situ gelling solution. – SA solutions (0.5–1.0 %, m/V) were prepared
in deionized water by heating to 60 °C under continuous stirring (3). After cooling be-
low 40 °C, various concentrations of CaCO3 and the drug were dispersed/dissolved un-
der continuous stirring. A few formulations were prepared in deionized water previously
containing 0.45 % (m/V) sodium citrate and 0.15 % (m/V) calcium chloride (Table I). The
resulting formulations were finally stored in amber coloured bottles until further use.
Viscosity of in situ gelling solutions. – The viscosity of formulations was determined
by a Brookfield viscometer DV-III (Brookfield, USA) using spindle number 21 with cup
and bob setting at 50 rpm (Table II).
Floating behavior. – The buoyancy lag time and buoyancy duration of the formula-
tions were determined in simulated gastric fluid (0.1 mol L–1 HCl, pH 1.2). The time in
minutes taken by the formulation to emerge on the dissolution medium surface (buoy-
ancy lag time) and buoyancy duration was noted.
Drug content. – Ten mL of the solution was added to 900 mL of simulated gastric
fluid (0.1 mol L–1 HCl, pH 1.2) and stirred for 1 h on a magnetic stirrer. The solution was
filtered, suitably diluted with simulated gastric fluid and the drug concentration was de-
termined by using a UV-visible spectrophotometer a (UV-1601 Shimadzu, Japan) at 226
nm against a suitable blank solution.
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In vitro release. – The release of ranitidine from the formulations was determined us-
ing a USP/24 dissolution test apparatus (Tab Machines, India) with a paddle stirrer at 50
rpm. The dissolution medium used was 900 mL of simulated gastric fluid (0.1 mol L–1
HCl, pH 1.2) and temperature was maintained at 37 ± 0.2 °C. Ten mL of the formulation
were placed into a Petri dish (4.5 cm i.d.) which was kept in the dissolution vessel and
simulated gastric fluid was carefully added to the vessel avoiding any disturbance of the
Petri dish. At each time interval, a precisely measured sample of the dissolution me-
dium was pipetted out and replenished with fresh medium. Ranitidine concentration
in the aliquot was determined spectrophotometrically. Each study was conducted in
triplicate (9).
Mechanism of drug release. – To analyze the mechanism of drug release from the formu-
lations, the in vitro dissolution data were fitted to zero-order (F = kt), first-order (F = e–kt),
Higuchi (F = k t), and Korsmeyer and Peppas (F = ktn) release models (10–12), where F
is the fraction of drug released ( 60%), k is the release constant and t is time.
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F1 Low 0.50 1.00 1.00 – –
F2 Low 0.75 1.00 1.00 – –
F3 Low 1.00 1.00 1.00 – –
F4 Medium 0.50 1.00 1.00 – –
F5 Medium 0.75 1.00 1.00 – –
F6 Medium 1.00 1.00 1.00 – –
F7 High 0.50 1.00 1.00 – –
F8 High 0.75 1.00 1.00 – –
F9 Low 0.75 1.00 0.50 – –
F10 Low 0.75 1.00 1.50 – –
F11 Low 0.75 2.00 1.00 – –
F12 Low 0.75 3.00 1.00 – –
F13 Low 0.75 1.00 1.00 0.15 0.45
F14 Medium 0.50 1.00 0.50 – –
F15 Medium 0.50 1.00 1.50 – –
F16 Medium 0.50 2.00 1.00 – –
F17 Medium 0.50 3.00 1.00 – –
F18 Medium 0.50 1.00 1.00 0.15 0.45
RESULTS AND DISCUSSION
The viscosity of the formulations increased with an increase in sodium alginate con-
centration (Table II) from 0.5–1 % (m/V) within each grade (low, medium and high vis-
cosity grades). This phenomenon is a consequence of increasing chain interaction with
an increase in polymer concentration. Calcium carbonate, which is the source of cations,
increased the viscosity of the formulation. This change in viscosity is due to the propor-
tional increase in the amount of dispersed calcium carbonate.
The buoyancy lag time varied with the formulation variables. Formulation F10 (SA
0.75 % m/V, CaCO3 1.5 % m/V) exhibited the least buoyancy lag time (17 s) while formu-
lation F17 (SA 0.50 % m/V, CaCO3 1 % m/V) exhibited the highest lag time (318 s) (Table
II). The decrease in the buoyancy lag time of an formulation F10 can be attributed to the
availability of an increased amount of CO2 as the concentration of calcium carbonate
was increased, being entrapped in the formed gel to give rapid buoyancy. Irrespective of
formulation variables, buoyancy duration was > 24 hours. The buoyancy lag time in-
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(%)bLag time (s) Duration (h)
F1 0.292 29 >24 101.9±1.1
F2 0.593 35 >24 99.4±0.6
F3 0.897 44 >24 97.6±0.3
F4 0.812 36 >24 97.6±0.9
F5 0.987 110 >24 99.5±1.3
F6 ND 226 >24 119.6±1.7
F7 0.995 175 >24 104.4±0.4
F8 0.812 226 >24 100.8±0.3
F9 0.245 316 >24 102.1±0.5
F10 0.985 17 >24 99.9±0.3
F11 0.503 205 >24 100.5±0.7
F12 0.413 317 >24 101.8±0.2
F13 0.696 22 >24 102.3±0.3
F14 0.326 265 >24 100.2±0.3
F15 ND 102 >24 102.1±0.3
F16 0.732 268 >24 101.8±0.3
F17 0.326 318 >24 112.7±0.2
F18 ND 240 >24 98.9±0.4
ND – not determined.
a 50 rpm.
b Mean of three trials ± SD.
creased with an increase in SA viscosity and concentration (1.0 > 0.75 > 0.5 % m/V). As
the drug concentration was increased from 1–3 % m/V, the buoyancy lag time also in-
creased from 35 to 318 seconds. It appears that with higher polymer content, excipients
and drug, the bulk density of the gel increased, resulting in extension of the lag time
from a few seconds to minutes.
In vitro drug release study was conducted on the formulations for a period of 8
hours during which the highest drug release of 96.5 ± 0.3 % (n = 3) was observed with
formulation F1 (SA 0.5 % m/V, drug 1 % m/V) and the least drug release of 74.1 ± 0.1 %
with F13 (SA 0.75 % m/V, drug 1 % m/V) during the 8 hour dissolution study. The influ-
ence of SA grades on in vitro drug release is shown in Figure 1. As the viscosity of the SA
used in the formulation was increased from low to high, a decrease in the amount of
drug release was observed. The drug release from the formulations with highly viscous
SA was slower compared to formulations with medium and low viscous SA.
Figure 1 shows the cumulative percentage drug release from formulations contain-
ing different levels of sodium alginate. The drug release decreased with an increase in
SA concentration in each grade. This can be explained by the fact that as the concentra-
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Fig. 1. Effect of SA grades and concentration on in vitro drug release from: a) F1–F3 and F7, F8, b)
F4–F6 (mean ± SD, n = 3).
tion of polymer increases, more polymeric chains are available for crosslinking with the
calcium ion. As the crosslinking increases, it forms a stronger gel, across which drug dif-
fusion becomes difficult (13, 14). Among the eight formulations studied (F1 to F8) using
different grades of sodium alginate, formulations F2 (SA low viscous, 0.75 % m/V) and
F4 (SA medium viscous, 0.5 % m/V) were selected for further studies based on their vis-
cosity, floating behaviour and in vitro drug release.
Calcium carbonate (0.5–1.0 % m/V) was used as a gas generating agent and a source
of cations for gelation in the formulation. Calcium ions cause in situ gelation by interact-
ing with sodium alginate during which carbon dioxide is entrapped within this gel ma-
trix attributing to the gel buoyancy. The desired buoyancy (> 24 h) was achieved with
calcium carbonate concentration of 0.5 % (m/V) while a concentration up to 1.5 % (m/V)
provided sustained release of ranitidine (Fig. 2). The drug release decreased as the con-
centration of calcium carbonate in the formulation was increased. This may be attri-
buted to the fact that as the concentration of calcium ions increases, cross-linking also in-
creases. Although formulations F2 and F10 contain the same proportion of low viscous
sodium alginate (0.75 % m/V), they differed in the calcium carbonate concentration. It is
likely that the entire carboxylic acid group is cross-linked by free Ca2+ ions when added
in a concentration of 1 % m/V (formulation F2). Therefore, addition of a higher propor-
tion of Ca2+ source in formulation F10 (1.5 % m/V) might not have altered the cross-link-
ing density, which could be the reason for the observed not significant change in drug
release from formulations F2 and F10.
Ranitidine was incorporated in three different concentrations (1, 2 and 3 % m/V) to
evaluate the effect of drug loading on the release profile (Fig. 3). An initial burst release
of ~60 % was observed from the studied formulations F2 (drug 1 % m/V), F11 (drug 2 %
m/V) and F12 (drug 3 % m/V) representing low viscous SA and F4 (drug 1 % m/V), F16
(drug 2 % m/V) and F17 (drug 3 % m/V) representing medium viscous SA. However, at
the end of 8 hours, the drug release from the formulations with low viscous SA was in
the range of 77–86 % and formulations with medium viscous SA ranged between 87–93 %.
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Fig. 2. Effect of calcium carbonate concentration on drug release from the formulations (mean ± SD,
n = 3).
This indicates that, except for the initial burst release which was due to the channel-
ing effect of ranitidine, the drug release in the next 5 hours was significantly sustained
(p < 0.05).
Fig. 4 shows the comparative drug release profiles of formulations with (F13 and
F18) and without (F2 and F4) sodium citrate (0.45 %, m/V) and calcium chloride (0.15
%, m/V). Incorporation of sodium citrate and calcium chloride in the formulations, fur-
ther sustained the drug release irrespective of the sodium alginate viscosity. This de-
crease in drug release was due to the availability of additional calcium ions supplied
by the incorporation of CaCl2 in the formulation, which further increased the extent of
gelation.
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Fig. 3. Effect of drug loading on drug release from the prepared formulations (mean ± SD, n = 3).



























Fig. 4. Effect of incorporation of sodium citrate and calcium chloride on drug release from the for-
mulations (mean ± SD, n = 3).
As shown in Table III, the coefficient of determinations (R2) for the zero-order model
ranges from 0.7733 to 0.9497 and that for the Higuchi model ranges from 0.8701 to 0.9911,
suggesting the square root of the Higuchi time model for drug release from dosage
forms. The drug release was further analyzed by the Korsmeyer-Peppas model to define
the mechanism of drug release; n values obtained were in the range of 0.15–0.42, which
further confirms the drug release by the diffusion mechanism.
CONCLUSIONS
In the present study, various in situ liquid oral formulations of ranitidine were pre-
pared. The study has shown that by modifying parameters like the initial drug loading,
concentration of gas generating agent and polymer content, the release can be modu-
lated to the desired rate. By observing various evaluation parameters for the studied for-
mulations, it can be stated that incorporation of sodium citrate and calcium chloride in
the formulations is required to control and sustain the drug release from in situ gel.
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F1 0.8395 0.8010 0.9225 0.1579
F2 0.9315 0.8799 0.9821 0.2840
F3 0.9290 0.8801 0.9816 0.3073
F4 0.8975 0.8342 0.9640 0.3267
F5 0.9054 0.8402 0.9646 0.3233
F6 0.8986 0.8303 0.9628 0.3852
7F 0.9164 0.8930 0.9607 0.1560
F8 0.9351 0.9110 0.9579 0.2082
F9 0.9155 0.8689 0.9697 0.2301
F10 0.9315 0.8811 0.9807 0.3325
F11 0.7733 0.7360 0.8701 0.1473
F12 0.9145 0.8839 0.9659 0.1663
F13 0.9051 0.8539 0.9680 0.2820
F14 0.8678 0.8145 0.9398 0.2250
F15 0.9315 0.7901 0.9303 0.2800
F16 0.9459 0.9098 0.9772 0.2390
F17 0.9038 0.8526 0.9677 0.2570
F18 0.9201 0.8629 0.9761 0.3294
a Mean of three trials ± SD. After 8 hours.
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S A _0length E T A K
Isporuka teku}eg pripravka H2-antagonista s lokalnim djelovanjem:
Primjena teku}eg ljekovitog oblika koji gelira in situ
GANAPATI ROHITH, BHIMAGONI KESHAVAMURTHY SRIDHAR i ANEGUNDHA SRINATHA
U radu je opisana priprava teku}eg pripravka za kontroliranu isporuku ranitidina s
produljenim zadr`avanjem u `elucu. Pripravak gelira in situ, a na~injen je iz natrijeva
alginata niske, srednje i visoke viskoznosti, kalcijeva karbonata (izvor kationa) i ranitidi-
na. Pripravcima je ispitana viskoznost, vrijeme plutanja, sadr`aj ranitidina i osloba|anje
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ljekovite tvari in vitro. Koncentracije natrijeva alginata, kalcijeva karbonata i ljekovite tvari
zna~ajno utje~u na viskoznost, vrijeme plutanja i osloba|anje ranitidina. Utvr|eno je da
se ljekovita tvar iz gela osloba|a difuzijom.
Klju~ne rije~i: gastroretencija, in situ geliranje, natrijev alginat, ranitidin
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